Accession Thera raises $40 million to advance immunotherapy platform

Accession Therapeutics, a UK clinical-stage biopharmaceutical company developing next generation cancer immunotherapies, announces it has raised £30.5 million ($40 million) from its existing investors.

Accession Therapeutics’ tumor-targeted immunotherapy platform, TROCEPT, is designed to activate the immune system in solid tumors that are resistant to conventional treatment. By combining targeted viral delivery with localized immune activation only in tumours, TROCEPT offers a potent, selective and scalable approach.

Proceeds from the financing will be used to advance Accession Therapeutics’ growing pipeline of first-in-class immunotherapies developed using the platform. This includes enabling the company to generate full clinical data from its ongoing Phase I ATTEST study of TROCEPT-01 (ATTR-01), the company’s lead program designed to selectively generate a clinically validated checkpoint inhibitor within advanced solid tumors. Funds will also be used to progress TROCEPT-02 into the clinic. This second program is designed to deliver a proprietary genetically encoded universal bispecific T cell engager into tumors.